Report ID: IBI1596129 | Category: Pharma & Healthcare | Pages: 130 | Format: PDF | Published Date: August 16,2023
1 Market Overview 1.1 Product Overview and Scope of Immuno-oncology Therapy 1.2 Classification of Immuno-oncology Therapy by Type 1.2.1 Overview: Global Immuno-oncology Therapy Market Size by Type: 2020 Versus 2021 Versus 2026 1.2.2 Global Immuno-oncology Therapy Revenue Market Share by Type in 2020 1.2.3 Monoclonal Antibodies 1.2.4 Immune Checkpoint Inhibitors 1.2.5 Immune System Modulators 1.2.6 Cancer Vaccines 1.3 Global Immuno-oncology Therapy Market by Application 1.3.1 Overview: Global Immuno-oncology Therapy Market Size by Application: 2020 Versus 2021 Versus 2026 1.3.2 Hospitals 1.3.3 Ambulatory Surgical Center 1.3.4 Others 1.4 Global Immuno-oncology Therapy Market Size & Forecast 1.5 Global Immuno-oncology Therapy Market Size and Forecast by Region 1.5.1 Global Immuno-oncology Therapy Market Size by Region: 2016 VS 2021 VS 2026 1.5.2 Global Immuno-oncology Therapy Market Size by Region, (2016-2021) 1.5.3 North America Immuno-oncology Therapy Market Size and Prospect (2018-2030) 1.5.4 Europe Immuno-oncology Therapy Market Size and Prospect (2018-2030) 1.5.5 Asia-Pacific Immuno-oncology Therapy Market Size and Prospect (2018-2030) 1.5.6 South America Immuno-oncology Therapy Market Size and Prospect (2018-2030) 1.5.7 Middle East and Africa Immuno-oncology Therapy Market Size and Prospect (2018-2030) 1.6 Market Drivers, Restraints and Trends 1.6.1 Immuno-oncology Therapy Market Drivers 1.6.2 Immuno-oncology Therapy Market Restraints 1.6.3 Immuno-oncology Therapy Trends Analysis 2 Company Profiles 2.1 Amgen 2.1.1 Amgen Details 2.1.2 Amgen Major Business 2.1.3 Amgen Immuno-oncology Therapy Product and Solutions 2.1.4 Amgen Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.1.5 Amgen Recent Developments and Future Plans 2.2 AstraZeneca 2.2.1 AstraZeneca Details 2.2.2 AstraZeneca Major Business 2.2.3 AstraZeneca Immuno-oncology Therapy Product and Solutions 2.2.4 AstraZeneca Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.2.5 AstraZeneca Recent Developments and Future Plans 2.3 Bristol-Myers Squibb 2.3.1 Bristol-Myers Squibb Details 2.3.2 Bristol-Myers Squibb Major Business 2.3.3 Bristol-Myers Squibb Immuno-oncology Therapy Product and Solutions 2.3.4 Bristol-Myers Squibb Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.3.5 Bristol-Myers Squibb Recent Developments and Future Plans 2.4 Eli-Lilly 2.4.1 Eli-Lilly Details 2.4.2 Eli-Lilly Major Business 2.4.3 Eli-Lilly Immuno-oncology Therapy Product and Solutions 2.4.4 Eli-Lilly Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.4.5 Eli-Lilly Recent Developments and Future Plans 2.5 Roche 2.5.1 Roche Details 2.5.2 Roche Major Business 2.5.3 Roche Immuno-oncology Therapy Product and Solutions 2.5.4 Roche Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.5.5 Roche Recent Developments and Future Plans 2.6 GlaxoSmithKline 2.6.1 GlaxoSmithKline Details 2.6.2 GlaxoSmithKline Major Business 2.6.3 GlaxoSmithKline Immuno-oncology Therapy Product and Solutions 2.6.4 GlaxoSmithKline Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.6.5 GlaxoSmithKline Recent Developments and Future Plans 2.7 Janssen Biotech 2.7.1 Janssen Biotech Details 2.7.2 Janssen Biotech Major Business 2.7.3 Janssen Biotech Immuno-oncology Therapy Product and Solutions 2.7.4 Janssen Biotech Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.7.5 Janssen Biotech Recent Developments and Future Plans 2.8 Merck 2.8.1 Merck Details 2.8.2 Merck Major Business 2.8.3 Merck Immuno-oncology Therapy Product and Solutions 2.8.4 Merck Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.8.5 Merck Recent Developments and Future Plans 2.9 Novartis 2.9.1 Novartis Details 2.9.2 Novartis Major Business 2.9.3 Novartis Immuno-oncology Therapy Product and Solutions 2.9.4 Novartis Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.9.5 Novartis Recent Developments and Future Plans 2.10 Pfizer 2.10.1 Pfizer Details 2.10.2 Pfizer Major Business 2.10.3 Pfizer Immuno-oncology Therapy Product and Solutions 2.10.4 Pfizer Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.10.5 Pfizer Recent Developments and Future Plans 2.11 Sanofi 2.11.1 Sanofi Details 2.11.2 Sanofi Major Business 2.11.3 Sanofi Immuno-oncology Therapy Product and Solutions 2.11.4 Sanofi Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.11.5 Sanofi Recent Developments and Future Plans 2.12 Spectrum Pharmaceuticals 2.12.1 Spectrum Pharmaceuticals Details 2.12.2 Spectrum Pharmaceuticals Major Business 2.12.3 Spectrum Pharmaceuticals Immuno-oncology Therapy Product and Solutions 2.12.4 Spectrum Pharmaceuticals Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.12.5 Spectrum Pharmaceuticals Recent Developments and Future Plans 2.13 Takeda 2.13.1 Takeda Details 2.13.2 Takeda Major Business 2.13.3 Takeda Immuno-oncology Therapy Product and Solutions 2.13.4 Takeda Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.13.5 Takeda Recent Developments and Future Plans 2.14 BioNTech SE 2.14.1 BioNTech SE Details 2.14.2 BioNTech SE Major Business 2.14.3 BioNTech SE Immuno-oncology Therapy Product and Solutions 2.14.4 BioNTech SE Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.14.5 BioNTech SE Recent Developments and Future Plans 2.15 Allogene Therapeutics 2.15.1 Allogene Therapeutics Details 2.15.2 Allogene Therapeutics Major Business 2.15.3 Allogene Therapeutics Immuno-oncology Therapy Product and Solutions 2.15.4 Allogene Therapeutics Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.15.5 Allogene Therapeutics Recent Developments and Future Plans 2.16 IMAB-I-Mab Biopharma Co., Ltd. 2.16.1 IMAB-I-Mab Biopharma Co., Ltd. Details 2.16.2 IMAB-I-Mab Biopharma Co., Ltd. Major Business 2.16.3 IMAB-I-Mab Biopharma Co., Ltd. Immuno-oncology Therapy Product and Solutions 2.16.4 IMAB-I-Mab Biopharma Co., Ltd. Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.16.5 IMAB-I-Mab Biopharma Co., Ltd. Recent Developments and Future Plans 2.17 Arcus Biosciences 2.17.1 Arcus Biosciences Details 2.17.2 Arcus Biosciences Major Business 2.17.3 Arcus Biosciences Immuno-oncology Therapy Product and Solutions 2.17.4 Arcus Biosciences Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.17.5 Arcus Biosciences Recent Developments and Future Plans 2.18 Gritstone Oncology 2.18.1 Gritstone Oncology Details 2.18.2 Gritstone Oncology Major Business 2.18.3 Gritstone Oncology Immuno-oncology Therapy Product and Solutions 2.18.4 Gritstone Oncology Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.18.5 Gritstone Oncology Recent Developments and Future Plans 2.19 Autolus Therapeutics 2.19.1 Autolus Therapeutics Details 2.19.2 Autolus Therapeutics Major Business 2.19.3 Autolus Therapeutics Immuno-oncology Therapy Product and Solutions 2.19.4 Autolus Therapeutics Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.19.5 Autolus Therapeutics Recent Developments and Future Plans 2.20 Rubius Therapeutics 2.20.1 Rubius Therapeutics Details 2.20.2 Rubius Therapeutics Major Business 2.20.3 Rubius Therapeutics Immuno-oncology Therapy Product and Solutions 2.20.4 Rubius Therapeutics Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2021-2023) 2.20.5 Rubius Therapeutics Recent Developments and Future Plans 3 Market Competition, by Players 3.1 Global Immuno-oncology Therapy Revenue and Share by Players (2021-2023) 3.2 Market Concentration Rate 3.2.1 Top 3 Immuno-oncology Therapy Players Market Share 3.2.2 Top 10 Immuno-oncology Therapy Players Market Share 3.2.3 Market Competition Trend 3.3 Immuno-oncology Therapy Players Head Office, Products and Services Provided 3.4 Mergers & Acquisitions 3.5 New Entrants and Expansion Plans 4 Market Size Segment by Type 4.1 Global Immuno-oncology Therapy Revenue and Market Share by Type (2016-2021) 4.2 Global Immuno-oncology Therapy Market Forecast by Type (2021-2026) 5 Market Size Segment by Application 5.1 Global Immuno-oncology Therapy Revenue Market Share by Application (2016-2021) 5.2 Immuno-oncology Therapy Market Forecast by Application (2021-2026) 6 North America by Country, by Type, and by Application 6.1 North America Immuno-oncology Therapy Revenue by Type (2018-2030) 6.2 North America Immuno-oncology Therapy Revenue by Application (2018-2030) 6.3 North America Immuno-oncology Therapy Market Size by Country 6.3.1 North America Immuno-oncology Therapy Revenue by Country (2018-2030) 6.3.2 United States Immuno-oncology Therapy Market Size and Forecast (2018-2030) 6.3.3 Canada Immuno-oncology Therapy Market Size and Forecast (2018-2030) 6.3.4 Mexico Immuno-oncology Therapy Market Size and Forecast (2018-2030) 7 Europe by Country, by Type, and by Application 7.1 Europe Immuno-oncology Therapy Revenue by Type (2018-2030) 7.2 Europe Immuno-oncology Therapy Revenue by Application (2018-2030) 7.3 Europe Immuno-oncology Therapy Market Size by Country 7.3.1 Europe Immuno-oncology Therapy Revenue by Country (2018-2030) 7.3.2 Germany Immuno-oncology Therapy Market Size and Forecast (2018-2030) 7.3.3 France Immuno-oncology Therapy Market Size and Forecast (2018-2030) 7.3.4 United Kingdom Immuno-oncology Therapy Market Size and Forecast (2018-2030) 7.3.5 Russia Immuno-oncology Therapy Market Size and Forecast (2018-2030) 7.3.6 Italy Immuno-oncology Therapy Market Size and Forecast (2018-2030) 8 Asia-Pacific by Region, by Type, and by Application 8.1 Asia-Pacific Immuno-oncology Therapy Revenue by Type (2018-2030) 8.2 Asia-Pacific Immuno-oncology Therapy Revenue by Application (2018-2030) 8.3 Asia-Pacific Immuno-oncology Therapy Market Size by Region 8.3.1 Asia-Pacific Immuno-oncology Therapy Revenue by Region (2018-2030) 8.3.2 China Immuno-oncology Therapy Market Size and Forecast (2018-2030) 8.3.3 Japan Immuno-oncology Therapy Market Size and Forecast (2018-2030) 8.3.4 South Korea Immuno-oncology Therapy Market Size and Forecast (2018-2030) 8.3.5 India Immuno-oncology Therapy Market Size and Forecast (2018-2030) 8.3.6 Southeast Asia Immuno-oncology Therapy Market Size and Forecast (2018-2030) 8.3.7 Australia Immuno-oncology Therapy Market Size and Forecast (2018-2030) 9 South America by Country, by Type, and by Application 9.1 South America Immuno-oncology Therapy Revenue by Type (2018-2030) 9.2 South America Immuno-oncology Therapy Revenue by Application (2018-2030) 9.3 South America Immuno-oncology Therapy Market Size by Country 9.3.1 South America Immuno-oncology Therapy Revenue by Country (2018-2030) 9.3.2 Brazil Immuno-oncology Therapy Market Size and Forecast (2018-2030) 9.3.3 Argentina Immuno-oncology Therapy Market Size and Forecast (2018-2030) 10 Middle East & Africa by Country, by Type, and by Application 10.1 Middle East & Africa Immuno-oncology Therapy Revenue by Type (2018-2030) 10.2 Middle East & Africa Immuno-oncology Therapy Revenue by Application (2018-2030) 10.3 Middle East & Africa Immuno-oncology Therapy Market Size by Country 10.3.1 Middle East & Africa Immuno-oncology Therapy Revenue by Country (2018-2030) 10.3.2 Turkey Immuno-oncology Therapy Market Size and Forecast (2018-2030) 10.3.3 Saudi Arabia Immuno-oncology Therapy Market Size and Forecast (2018-2030) 10.3.4 UAE Immuno-oncology Therapy Market Size and Forecast (2018-2030) 11 Research Findings and Conclusion 12 Appendix 12.1 Methodology 12.2 Research Process and Data Source 12.3 Disclaimer
It contains all the geographic trends, and market analysis for global market